- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA accepts Imation’s reply to warning
Imation of Oakdale, MN, announced June 11 that the Food and Drug Administration has accepted its plan for dealing with concerns outlined in a warning letter it received from the FDA last month (SCAN 6/10/98). The letter was the result of a
Imation of Oakdale, MN, announced June 11 that the Food and Drug Administration has accepted its plan for dealing with concerns outlined in a warning letter it received from the FDA last month (SCAN 6/10/98). The letter was the result of a scheduled FDA visit in April to Imation's laser printer manufacturing facility, where the agency discovered inadequate links between Imation's documentation systems. In its reply, the company detailed a consistent documentation system that satisfies FDA requirements and clarified the connections between its existing documentation systems.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
